Articles On Neuren Pharmaceuticals (ASX:NEU)

If you're in the market for some new ASX 200 shares in July, then it could be worth listening to what analysts at Bell Potter are saying. That's because they have just revealed their favoured picks for the month ahead. Three on its list t...

In this article, we examine the best ASX 200 healthcare shares of FY24 based on share price growth. Here are the best performers, according to data from S & P Global Market Intelligence. The top 3 ASX 200 healthcare shares of FY2...

When we compare the capital growth of ASX 200 shares vs. property in FY24, bricks and mortar comes out on top… but only just. The S&P/ASX 200 Index (ASX: XJO) rose from a closing value of 7,203.3 points on the last trading day of FY...

If you are lucky enough to have $10,000 burning a hole in your pocket, it could be worth putting it to work in the share market. After all, over the long term, the share market has generated an average return of approximately 10% per annum....

A new financial year is on the horizon, so what better time to make some new additions to your investment portfolio. But which ASX 200 stocks could be buys? Let's take a look at three best buys for FY 2025 according to analysts at Bell Pott...

It was a decent end to what was a tough trading week for ASX shares and the S&P/ASX 200 Index (ASX: XJO) this Friday. After suffering a few drops this week, investors turne...

ASX health stocks rise in past five days, despite May uptick in inflation  Healius downgrades guidance for FY24, citing inflationary pressures Immutep falls despite positive results from Phase 2 trial in first line head and neck cancer He...

It was an unpleasant Wednesday for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares this hump day. After enjoying a strong session yesterday, investors reversed course to...

I joined Adam Keily on the ‘Equity Mates’ podcast to discuss eight small-cap stocks, share my insights on their performance and answer whether I would buy or sell them. In this episode, we delve into the factors influencing each company pro...

Vinay Ranjan from Airlie Funds Management says investors should ignore industry predictions for where ASX 200 shares might go in the new financial year and instead simply focus on buying quality companies. Ranjan says attempting to profi...

ASX 200 healthcare stock Neuren Pharmaceuticals Ltd (ASX: NEU) has posted impressive gains over the past year but one director appears to still see value in today's share price. Neuren shares closed the session on Thursday at $19.31, up...

Looking to invest in an ASX biotech share with the potential to become the next Telix Pharmaceuticals Ltd (ASX: TLX)? You're not alone! The S&P/ASX 200 Index (ASX: XJO) biopharmaceutical company has been going from strength to st...

ASX health stocks fall in past five days in line with broader markets as investors spooked by hotter than expected inflation Dimerix up 33% for week after inking second exclusive license deal for commercialisation of its Phase 3 kidney dis...

If you want to give your investment portfolio a nice boost, then it could be worth considering the ASX shares listed below. That's because they have been named as buys and tipped to rise materially from current levels. Here's what you need...

The ASX200 didn’t seem to be able to recover from the CPI inflation data (April) read – showing a rise to 3.6 per cent – which was hotter than many had forecast. The index lost more than 1.15 per cent – all sectors were down with Consume...

The S&P/ASX 200 Index (ASX: XJO) is having a very tough session on Wednesday. In response to the release of a hotter than expected inflation reading, the benchmark index is down 1.35% to 7,661.5 points. Four ASX shares that are falling...

Neuren Pharmaceuticals (ASX:NEU) has reported positive results from a Phase 2 trial of NNZ-2591 in children with Pitt-Hopkins syndrome.

ASX biotech shares have been showing significant signs of momentum lately. Exciting clinical trial results and strong investor interest are propelling the sector forward. Plenty of upcoming catalysts and company-specific developments could...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price was in fine form on Monday. The ASX 200 pharma stock ended the day almost 16% higher at $23.97. This means that Neuren Pharmaceuticals' shares are now up 78% since this time last year. I...

On Monday, the S&P/ASX 200 Index (ASX: XJO) started the week in a very positive fashion. The benchmark index rose 0.8% to 7,788.3 points. Will the market be able to build on this on Tuesday? Here are five things to watch: ASX 200 expec...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a strong start to the trading week this Monday, turning things around from the sour end to last week. The ASX 200 appeared well-rested after the weeken...

ASX in broad rebound; Cettire, Neuren, and Lendlease lead surge Positive sentiment follows Wall Street strength DY6 Metals up 300pc on  Rare Earths find at the Tundulu project in Malawi   Aussie shares rebounded pretty much across the boa...

The S&P/ASX 200 Index (ASX: XJO) is having a strong start to the week. In afternoon trade, the benchmark index is up 0.8% to 7,786.8 points. Four ASX shares that are rising more than most today are listed below. Here's why they are ra...

The S&P/ASX 200 Index (ASX: XJO) is up a very healthy 0.8% today, but this ASX 200  healthcare share is leaving those gains wanting. Shares in the biopharmaceutical company closed on Wednesday trading for $20.71. The stock then...

Last Monday marked Clinical Trials Day, when the world’s healing profession celebrated the work of Royal Navy surgeon James Lind. The medical mariner was credited with carrying out the world’s first placebo-controlled clinical trial in 1747...

Xero and Nvidia buoyed Tech, while BHP dragged Mining Gold stocks were the worst performing miners today New tensions over China’s drills near Taiwan   The benchmark ASX 200 index was down about -0.50% on Thursday. Xero’s (ASX:XRO) 10% ju...

One of the highest growth ASX 200 healthcare stocks on the market went into a trading halt on Thursday. Neuren Pharmaceuticals Ltd (ASX: NEU) requested the trading halt before the market open today. The company said it wanted time t...

Do you remember how the COVID-19 market crash began, with ASX 200 shares plummeting almost 700 points in just five trading days? Oh, the shivers up my spine! And that was just the start of it, too. ASX 200 shares vs. property during...

I really like being gifted the data drops every month or so from the growing family of madly convenient broker platforms. I am also a huge fan of the ‘democratisation’ of stuff. These trading app-platform-thingys are a fine example. No long...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a successful hump day this Wednesday, rebounding after some heavy falls earlier in the week. By the end of trading, the...

ASX gained on the aftermath of Budget Silver stocks on a roll, along with other miners Market newbie Sun Silver hits the ground sprinting on debut   The ASX rose +0.5% on Wednesday on the aftermath of the Fed Budget. The local market also...

It was a dastardly Tuesday for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares during today's trading. The ASX 200 finished up with its tail between its legs...

ASX retreats on Tuesday ahead of Fed Budget and US PPI/CPI Copper stocks up after the metal hit highest level since 2022 GUD jumps 11pc after strong FY24 update   The ASX dipped by -0.4% on Tuesday ahead of the Federal Budget and a key PP...

Four S&P/ASX 300 Index (ASX: XKO) shares were just re-rated by top brokers. One operates in the credit-impaired consumer debt segment. The second is a biopharmaceutical company. The third provides vehicle fleet leasing, fleet management...

ASX health stock rise  in past five days along with broader markets  Wound care company Polynovo achieves its first ever $10m+ revenue month in April Power says Neuren selloff a “complete overreaction” after US partner Arcadia’s latest res...

It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX sha...

The S&P/ASX 200 Index (ASX: XJO) has returned to form on Friday. In afternoon trade, the benchmark index is up 0.5% to 7,759.5 points. Four ASX shares that have failed to follow the market higher today are listed below. Here's why they...

Imricor has two upcoming pivotal trials and is looking to transform cardiac ablation procedures  Botanix Pharmaceuticals is expecting US FDA approval for its lead dermatology product Sofdra in late June Bell Potter is confident in Paradigm...

ASX losses accelerate after sluggish retail sector updates  Baby Bunting, Temple & Webster, JB Hi-fi all under pressure on soft sales Alliance Nickel soars on fat federal grant   After opening modestly higher this morning, the ASX qui...

It was the ASX 200 healthcare stock of the year in 2023, with its share price catapulting 214% in just 12 months. But today is a challenging one for Neuren Pharmaceuticals Ltd (ASX: NEU), with its share price crashing 10.6% to an intra...

Neuren Pharma’s Q1 DAYBUE sales disappoint 4DMedical’s CT LVAS technology gets reimbursement in US Melodiol’s Canadian subsidiary, Mernova, continues to make strong progress   Neuren’s Q1 disappoints Neuren Pharma (ASX:NEU) slumped by ove...

Neurotech’s NTIRTT1 becomes first clinical trial to show statistically significant clinical improvement in Rett Syndrome patients with a broad-spectrum cannabinoid drug Company’s NTI164 compares favourably to DAYBUE, the only FDA-approved...

Share tips and stock recommendations for the Australian (ASX) share market – buy, hold, and sell. Michael Gable is an expert guest commentator for the stock market newsletter thebull.com.au. This post is an extract from the newsletter dated...

Turning $100,000 into a million bucks might sound like magic. But no one needs supernatural powers if they use ASX shares and compounding to their advantage. Allow me to introduce you to three stocks that I reckon could do the trick: Tempo...

If you've been a bunny and missed out on the 3.45% gains already delivered by the S&P/ASX 200 Index (ASX: XJO) so far in 2024, fear not! Because, right now is an egg-cellent time to treat yourself to some sweet new investments. But rem...

When an S&P/ASX 200 Index (ASX: XJO) stock outperforms all and sundry one year but then suddenly dips, you need to at least check out what's happening. Neuren Pharmaceuticals Ltd (ASX: NEU) was the highest climber in the ASX 200 last y...

The green graphics card giant is making a motza. But did you know some ASX companies have even bigger profit margins than Nvidia Corp (NASDAQ: NVDA)? Masterfully riding the AI wave, Nvidia looks like the Kelly Slater of computer hardware....

Many Australians have the impression that investing in stocks is only for rich people.  But that cannot be further from the truth. If you have just $500 you could make a pretty useful start to a portfolio. I have taken the liberty of picki...

It's been a horror end to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Friday. The ASX 200 fell sharply at market open, dropping as muc...